MA33260B1 - 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines - Google Patents

6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines

Info

Publication number
MA33260B1
MA33260B1 MA34332A MA34332A MA33260B1 MA 33260 B1 MA33260 B1 MA 33260B1 MA 34332 A MA34332 A MA 34332A MA 34332 A MA34332 A MA 34332A MA 33260 B1 MA33260 B1 MA 33260B1
Authority
MA
Morocco
Prior art keywords
azabicyclo
hex
phenylpyrimidines
platletary
cerebrovascular
Prior art date
Application number
MA34332A
Other languages
English (en)
Inventor
Eva Caroff
Kurt Hilpert
Francis Hubler
Emmanuel Meyer
Dorte Renneberg
Original Assignee
Actelion Pharmaceuticals Ltd
Saba & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd, Saba & Co filed Critical Actelion Pharmaceuticals Ltd
Publication of MA33260B1 publication Critical patent/MA33260B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'INVENTION PORTE SUR DES DÉRIVÉS 6-(3-AZABICYCLO[3.1.0]HEX-3-YL)-2-PHÉNYLPYRIMIDINES ET SUR LEUR UTILISATION COMME ANTAGONISTES DU RÉCEPTEUR P2Y12 DANS LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES VASCULAIRES PÉRIPHÉRIQUES, VISCÉRALES, HÉPATIQUES ET VASCULAIRES RÉNALES, CARDIOVASCULAIRES ET CÉRÉBROVASCULAIRES OU D'AFFECTIONS ASSOCIÉES À L'AGRÉGATION PLAQUETTAIRE, DONT LA THROMBOSE CHEZ L'HOMME ET D'AUTRES MAMMIFÈRES.
MA34332A 2009-04-08 2010-04-07 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines MA33260B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2009051486 2009-04-08
PCT/IB2010/051499 WO2010116328A2 (fr) 2009-04-08 2010-04-07 6-(3-azabicyclo[3.1.0]hex-3-yl)-2-phénylpyrimidines

Publications (1)

Publication Number Publication Date
MA33260B1 true MA33260B1 (fr) 2012-05-02

Family

ID=42936647

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34332A MA33260B1 (fr) 2009-04-08 2010-04-07 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines

Country Status (18)

Country Link
US (1) US8288385B2 (fr)
EP (1) EP2417128B1 (fr)
JP (1) JP5536873B2 (fr)
KR (1) KR101694563B1 (fr)
CN (1) CN102369197B (fr)
AU (1) AU2010233378A1 (fr)
BR (1) BRPI1014039A2 (fr)
CA (1) CA2756542C (fr)
CL (1) CL2011002467A1 (fr)
ES (1) ES2567311T3 (fr)
IL (1) IL215517A0 (fr)
MA (1) MA33260B1 (fr)
MX (1) MX2011010200A (fr)
NZ (1) NZ596213A (fr)
RU (1) RU2011144763A (fr)
SG (1) SG175075A1 (fr)
WO (1) WO2010116328A2 (fr)
ZA (1) ZA201108158B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
BRPI0819696B1 (pt) 2007-11-29 2018-10-23 Actelion Pharmaceuticals Ltd compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
KR101728180B1 (ko) 2009-04-22 2017-04-18 액테리온 파마슈티칼 리미티드 티아졸 유도체들 및 ｐ2ｙ12 수용체 길항제로서 이들의 용도
AR090259A1 (es) 2012-03-06 2014-10-29 Boehringer Ingelheim Int Inhibidores de benzodioxano de la produccion de leucotrieno para terapia de combinacion
US10420882B2 (en) * 2013-03-15 2019-09-24 Medovate Limited Method and system for controllably administering fluid to a patient and/or for controllably withdrawing fluid from the patient
JP6503515B2 (ja) 2015-12-29 2019-04-17 ファイザー・インク ケトヘキソキナーゼ阻害薬としての置換３−アザビシクロ［３．１．０］ヘキサン
AU2017319080B2 (en) 2016-08-31 2020-12-17 Eisai R&D Management Co., Ltd. Pyrazolo[1,5-a]pyrimidine compound
HUE057772T2 (hu) 2016-09-22 2022-06-28 Idorsia Pharmaceuticals Ltd Kristályos formák
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
AU2020214064B2 (en) 2019-01-29 2022-10-20 Shandong Xuanzhu Pharma Co., Ltd. Hexone glucokinase inhibitor and use thereof
US11274082B2 (en) 2019-05-31 2022-03-15 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2020243423A1 (fr) * 2019-05-31 2020-12-03 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
GB202001856D0 (en) * 2020-02-11 2020-03-25 Inorbit Therapeutics Ab Compounds useful in inhibiting ketohexokinase and methods of making and using the same
EP4196118A1 (fr) 2020-08-13 2023-06-21 Boehringer Ingelheim International GmbH Traitement de la déficience cognitive associée à la schizophrénie
CN117567449A (zh) 2020-10-13 2024-02-20 勃林格殷格翰国际有限公司 再加工方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
CA2507657C (fr) * 2002-12-11 2011-05-31 Bayer Schering Pharma Aktiengesellschaft Composes de 2-aminocarbonyl-quinoline utilises en tant qu'antagonistes du recepteur de l'adenosine diphosphate des plaquettes
PT1611144E (pt) 2003-04-09 2010-11-12 Wyeth Llc Derivados do ácido 2-(8,9-dioxo-2,6-diazabiciclo(5.2.0)- non-1(7)-eno-2-il)-alquil-fosfónico e sua utilização como antagonistas do receptor n-metil-d-aspartato (nmda)
TW200640877A (en) * 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
ES2421448T3 (es) 2005-10-21 2013-09-02 Actelion Pharmaceuticals Ltd Derivados de piperazina como agentes contra la malaria
US20100035863A1 (en) * 2006-09-12 2010-02-11 Ucb Pharma, S.A. 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
CA2684644A1 (fr) * 2007-04-23 2008-10-30 Sanofi-Aventis Derives de quinoleine-carboxamide comme antagonistes de p2y12
TW200911787A (en) * 2007-07-03 2009-03-16 Astrazeneca Ab New aza-bicyclohexane compounds useful as inhibitors of thrombin
BRPI0819696B1 (pt) 2007-11-29 2018-10-23 Actelion Pharmaceuticals Ltd compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto
JP5560202B2 (ja) 2007-12-26 2014-07-23 サノフイ Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体
JP5504171B2 (ja) 2007-12-26 2014-05-28 サノフイ Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
KR101728180B1 (ko) 2009-04-22 2017-04-18 액테리온 파마슈티칼 리미티드 티아졸 유도체들 및 ｐ2ｙ12 수용체 길항제로서 이들의 용도

Also Published As

Publication number Publication date
SG175075A1 (en) 2011-11-28
BRPI1014039A2 (pt) 2018-04-03
MX2011010200A (es) 2011-10-14
CA2756542C (fr) 2017-08-22
RU2011144763A (ru) 2013-05-20
JP2012523406A (ja) 2012-10-04
IL215517A0 (en) 2011-12-29
WO2010116328A2 (fr) 2010-10-14
WO2010116328A3 (fr) 2011-01-13
AU2010233378A1 (en) 2011-11-24
EP2417128B1 (fr) 2016-03-02
CL2011002467A1 (es) 2012-02-24
CN102369197B (zh) 2013-11-06
EP2417128A2 (fr) 2012-02-15
KR20120070627A (ko) 2012-06-29
NZ596213A (en) 2013-05-31
US20120028989A1 (en) 2012-02-02
KR101694563B1 (ko) 2017-01-09
US8288385B2 (en) 2012-10-16
JP5536873B2 (ja) 2014-07-02
ZA201108158B (en) 2014-04-30
CA2756542A1 (fr) 2010-10-14
ES2567311T3 (es) 2016-04-21
CN102369197A (zh) 2012-03-07

Similar Documents

Publication Publication Date Title
MA32277B1 (fr) Derives de 2-phenyl-4- cyclopropyl-pyrimidine
WO2010116328A3 (fr) 6-(3-azabicyclo[3.1.0]hex-3-yl)-2-phénylpyrimidines
MA30868B1 (fr) Derives de 2-aminocarbonyl-pyridine
MA33277B1 (fr) Dérivés de thiazole et leur utilisation comme antagonistes des récepteurs p2y12
MA33123B1 (fr) 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation
PH12013500564A1 (en) Anti-cd48 antibodies and uses thereof
MA30903B1 (fr) Derives de 2 - phenyl-6-minocarbonyl-pyrimidine
TW200640877A (en) Pyrimidine derivatives
EA201291441A1 (ru) Пробиотические штаммы для применения при улучшении состояния кишечной нервной системы
MY153749A (en) Phosphonic acid derivates and their use as p2y12 receptor antagonists
UA102065C2 (xx) Заміщені 4-арил-1,4-дигідро-1,6-нафтиридинаміди і їх застосування$замещенные 4-арил-1,4-дигидро-1,6-нафтиридинамиды и их применение
EP2486060A4 (fr) Anticorps anti-siglec 15 dans le traitement de maladies liées à une perte osseuse
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EP2485751A4 (fr) Procédés de traitement de la dépression et d'autres maladies associées
EA201270480A1 (ru) Новые соединения
MA35458B1 (fr) Variants du facteur de croissance des fibroblastes 21
IN2012DN02737A (fr)
EA201390830A1 (ru) Соединения и их применение в качестве ингибиторов фермента расщепления бета-сайта app (bace)
WO2011141823A3 (fr) Méthodes de traitement et/ou de prévention de troubles de prolifération cellulaire à l'aide d'antagonistes de il-17
MX2015002289A (es) Anticuerpos humanos para gfr alfa 3 y métodos para su uso.
MA38060A1 (fr) Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation
MA32282B1 (fr) Dérivés de 2-phényl-pyridine substitués
EA201492102A1 (ru) Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
UA109414C2 (uk) Арильовані камфени та фармацевтична композиція на їх основі
EA201291440A1 (ru) Пробиотические штаммы для применения при повышении трансэпителиального сопротивления